Compound: Ribociclib
SMILES: O=C(N(C)C)c1n(c2nc(Nc3ncc(N4CCNCC4)cc3)ncc2c1)C5CCCC5
InChIKey: RHXHGRAEPCAFML-UHFFFAOYSA-N
Synonyms: Ribociclib, 1211441-98-3, LEE011, LEE-011, 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, LEE011A, TK8ERE8P56, 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, LEE-011A, DTXSID201021027, ribociclibum, 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo(2,3-d)pyrimidine-6-carboxamide, RefChem:55976, L01XE42, DTXCID701506068, 807-111-0, Ribociclib (LEE011), LEE 011, Kisqali, 7-Cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, UNII-TK8ERE8P56, MFCD27976795, NVP-LEE011, 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide, C23H30N8O, 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide, 7-Cyclopentyl-N,N-dimethyl-2-(5-(piperazin-1-yl)pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, Ribociclib [INN], Ribociclib(LEE011), Ribociclib, LEE011, Ribociclib [USAN:INN], 6ZZ, 7H-Pyrrolo[2,3-d]pyrimidine-6-carboxamide, 7-cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-; 7-Cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; Kisqali; LEE 011; LEE 011A; Ribociclib, Ribociclib (Standard), RIBOCICLIB [MI], Ribociclib (USAN/INN), RIBOCICLIB [USAN], Ribociclib (LEE011)?, RIBOCICLIB [WHO-DD], SCHEMBL302310, GTPL7383, orb1300987, CHEMBL3545110, SCHEMBL29384231, SCHEMBL29385337, SCHEMBL29912679, EX-A304, CHEBI:230905, RHXHGRAEPCAFML-UHFFFAOYSA-N, BDBM148264, GLXC-90046, HMS3653N03, HMS3673I19, HMS3748M05, HMS5085P14, example 74 [US8962630], EBC-17108, HY-15777R, NSC778909, NSC794613, NSC800867, s7440, AKOS025404915, AKOS032949987, CCG-269070, CS-1750, DB11730, NSC-778909, NSC-794613, NSC-800867, SB18480, NCGC00386317-10, NCGC00386317-11, AC-30029, AS-10159, BP-44045, DA-35904, FR106414, HY-15777, NS00072964, SW220101-1, D10883, EN300-7409093, US8962630, 74, BRD-K36788280-001-01-2, BRD-K36788280-001-03-8, BRD-K36788280-001-04-6, Q27088552, 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-yl-2-pyridyl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide, 7H-Pyrrolo[2,3-d]pyrimidine-6-carboxamide, 7-cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, Kisqali,7H-Pyrrolo[2,3-d]pyrimidine-6-carboxamide, 7-cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, 7-Cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, Ribociclib, LEE 011A, LEE 011
Theoretical properties:
molecular_formula: C23H30N8O
molecular_weight: 434.5 g/mol
exact_mass: 434.25425761 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 5
heavy_atom_count: 32
topological_polar_surface_area: 91.2 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Ribociclib is a member of piperazines and a member of pyridines.
chembl: RIBOCICLIB is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals.
The most common side effects include infections, low levels of white blood cells, headache, cough, nausea (feeling sick), vomiting, diarrhea, constipation, tiredness, hair loss and rash.
Ribociclib was approved for medical use in the United States in March 2017, in the European Union in August 2017, and in the United Kingdom in February 2021.